[Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].

Abstract

Acromegaly is a disease caused by a pituitary tumor (somatotropinoma) or by ectopic secretion of GH or IGF-1. About 15% of tumors secrete not only GH but PRL as well. Last time a lanreotide and an octreotide (the somatostatine analogues) are useful in the therapy of acromegaly. We observed the influence of the lanreotide on GH and prolactin. We noticed that the lanreotide caused not only serum level reduction of a growth hormone but also prolactine in patients with mixed pituitary tumors.

• Authors: R Wasko, J Sawicka, C Stachowiak, W Kozak, R Junik, J Sowinski
• Journal: Annales d'endocrinologie (Ann Endocrinol (Paris)) Vol. 63 Issue 6 Pt 1 Pg. 532-5 (Dec 2002) ISSN: 0003-4266 [Print] France
• Vernacular Title: Influence du lanréotide sur la concentration sérique de prolactine chez les patients atteints de tumeurs somato-lactotropes.
• PMID: 12527855 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Peptides, Cyclic
• lanreotide
• Human Growth Hormone
• Somatostatin
• Prolactin
• Growth Hormone

Topics

• Acromegaly (drug therapy, etiology)
• Adult
• Antineoplastic Agents (therapeutic use)
• Female
• Follow-Up Studies
• Growth Hormone (metabolism)
• Human Growth Hormone (blood)
• Humans
• Male
• Middle Aged
• Peptides, Cyclic (therapeutic use)
• Pituitary Neoplasms (blood, drug therapy, metabolism)
• Prolactin (blood, metabolism)
• Somatostatin (analogs & derivatives, therapeutic use)
• Treatment Outcome